• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Vaxart Inc

    7/3/24 6:02:06 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VXRT alert in real time by email
    S-8 1 vxrt20240702_s8.htm FORM S-8 vxrt20240702_s8.htm

     

    As filed with the Securities and Exchange Commission on July 2, 2024

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    VAXART, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware

     

    59-1212264 

    (State or other jurisdiction of Incorporation or organization)

     

    (I.R.S. Employer Identification No.)

     

    170 Harbor Way, Suite 300

    South San Francisco, CA 94080

    (Address of principal executive offices) (Zip code)

     


     

    Vaxart, Inc. 2019 Equity Incentive Plan

    Vaxart, Inc. 2022 Employee Stock Purchase Plan

    (Full title of the plan)

     


     

    Steven Lo

    Chief Executive Officer

    170 Harbor Way, Suite 300

    South San Francisco, CA 94080

    (Name and address of agent for service)

     

    (650) 550-3500

    (Telephone number, including area code, of agent for service)

     


     

    Copies to:

    Faith L. Charles, Esq.

    Thompson Hine LLP

    300 Madison Avenue, 27th Floor

    New York, NY 10017-6232

    Telephone: (212) 344-5680

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer □

    Accelerated filer ☐

    Non-accelerated filer ☒  

    Smaller reporting company ☒

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is being filed by Vaxart, Inc. (the “Registrant”) for the purposes of (1) registering an additional 15,000,000 shares (the “Additional Plan Shares”) of the Registrant’s common stock, par value $0.0001 (“Common Stock”), that are issuable at any time or from time to time under the Registrant’s 2019 Equity Incentive Plan (as amended to date, the “Incentive Plan”), and (2) registering an additional 1,800,000 shares of Common Stock (the “Additional ESPP Shares”) that are issuable at any time or from time to time under the Registrant’s 2022 Employee Stock Purchase Plan (as amended to date, the “ESPP”).

     

    The Additional Plan Shares are authorized for issuance under the Incentive Plan pursuant to an amendment and restatement to the Incentive Plan which was approved by the Registrant’s stockholders at the 2024 annual meeting of stockholders held on June 11, 2024. The Additional ESPP Shares are authorized for issuance under the ESPP pursuant to an amendment and restatement to the ESPP which was also approved by the Registrant’s stockholders at the 2024 annual meeting of stockholders held on June 11, 2024.

     

    The Registrant previously filed: (i) a Registration Statement on Form S-8 (File No. 333-231013) with the U.S. Securities and Exchange Commission (the “SEC”) to register 1,600,000 shares of Common Stock for issuance pursuant to the Incentive Plan; (ii) a Registration Statement on Form S-8 (File No. 333-239727) with the SEC to register an additional 6,400,000 shares of Common Stock for issuance pursuant to the Incentive Plan; (iii) a Registration Statement on Form S-8 (File No. 333-257245) with the SEC to register an additional 8,900,000 shares of Common Stock for issuance pursuant to the Incentive Plan; and (iv) a Registration Statement on Form S-8 (File No. 333-267984) with the SEC to register an additional 12,000,000 shares of Common Stock for issuance pursuant to the Incentive Plan and to register 1,800,000 shares of Common Stock for issuance pursuant to the ESPP.

     

    Upon the effectiveness of this Registration Statement, an aggregate of 43,900,000 shares of Common Stock will be registered for issuance from time to time under the Incentive Plan, and an aggregate of 3,600,000 shares of Common Stock will be registered for issuance from time to time under the ESPP. The contents of the Registration Statements on Form S-8 (File Nos. 333-231013, 333-239727, 333-257245, and 333-267984) filed with the SEC on April 24, 2019, July 7, 2020, June 21, 2021, and October 24, 2022, respectively, are hereby incorporated by reference, except to the extent supplemented, amended, or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3.     INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

     

    The following documents filed by Registrant with the SEC are incorporated by reference into this Registration Statement:

     

     

    (a)

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 14, 2024.

     

     

    (b)

    The Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on May 13, 2024.

     

     

    (c)

    The definitive proxy statement relating to the Registrant’s 2024 annual meeting of stockholders, filed with the SEC on April 29, 2024.

     

     

    (d)

    The Registrant’s Current Reports on Form 8-K (and applicable amendments thereto) filed with the SEC on January 16, 2024, January 16, 2024, January 19, 2024, February 2, 2024, February 15, 2024, February 29, 2024, March 6, 2024, April 30, 2024, June 13, 2024, June 13, 2024, June 14, 2024, June 18, 2024, and June 20, 2024.

     

     

    (e)

    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 10, filed with the SEC on May 4, 1970, as amended by the Registrant’s Current Report on Form 8-K (File No. 000-04829) filed with the SEC on August 15, 2003.

     

     

    (f)

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 8.     EXHIBITS

     

    Exhibit
    Number

    Description of Document

    Schedule/Form

    File
    Number

    Exhibit

    Filing Date

    3.1

    Restated Certificate of Incorporation of Aviragen Therapeutics, Inc.

    10-K

    001-35285

    3.1

    September 13, 2016

    3.2

    Certificate of Amendment to Restated Certificate of Incorporation of Aviragen Therapeutics, Inc.

    8-K

    001-35285

    3.1

    February 20, 2018

    3.3

    Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc.

    8-K

    001-35285

    3.2

    February 20, 2018

    3.4

    Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc.

    8-K

    001-35285

    3.1

    April 24, 2019

    3.5

    Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc.

    8-K

    001-35285

    3.1

    June 9, 2020

    3.6

    Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc.

    10-Q

    001-35285

    3.3

    August 8, 2022

    3.7

    Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc.

    8-K

    001-35285

    3.1

    June 13, 2024

    3.8

    Amended and Restated Bylaws of Vaxart, Inc., effective as of October 18, 2023

    8-K

    001-35285

    3.1

    October 23, 2023

    4.1

    Reference is made to Exhibits 3.1 through 3.8

           

    4.2

    Specimen Common Stock Certificate

    S-3

    333-228910

    4.2

    December 20, 2018

    5.1*

    Opinion of Thompson Hine LLP

           

    10.1

    2019 Equity Incentive Plan, as amended

    8-K

    001-35285

    10.1

    June 13, 2024

    10.2

    2022 Employee Stock Purchase Plan, as amended

    8-K

    001-35285

    10.2

    June 13, 2024

    23.1*

    Consent of WithumSmith+Brown, PC, Independent Registered Public Accounting Firm

           

    23.2*

    Consent of Thompson Hine LLP (included in Exhibit 5.1)

           

    24.1*

    Power of Attorney. Reference is made to the signature page hereto.

           

    107*

    Filing Fee Table

           

     


    *

    Filed herewith.

     

     

     

     

    ITEM 9.     UNDERTAKINGS

     

    1.     The undersigned Registrant hereby undertakes:

     

    (a)     To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)     To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii)     To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement.

     

    (iii)     To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (b)     That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)     To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    2.     The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3.     Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on July 2, 2024.

     

     

    VAXART, INC.

       
     

    /s/ Steven Lo

     

    Steven Lo

     

    President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Steven Lo and Phillip E. Lee, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully and to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signatures

    Title

    Date

    /s/ Steven Lo

    Steven Lo

    President, Chief Executive Officer, and Director

    (Principal Executive Officer)

    July 2, 2024

         

    /s/ Phillip E. Lee

    Phillip E. Lee

    Chief Financial Officer

    (Principal Accounting Officer and Principal Financial Officer)

    July 2, 2024

         

    /s/ Michael J. Finney

    Michael J. Finney, Ph.D.

    Chair of the Board of Directors

    July 2, 2024

         

    /s/ Elaine J. Heron

    Elaine J. Heron, Ph.D.

    Director

    July 2, 2024

         

    /s/ W. Mark Watson

    W. Mark Watson, C.P.A.

    Director

    July 2, 2024

         

    /s/ David Wheadon

    David Wheadon, M.D.

    Director

    July 2, 2024

         

    /s/ Robert A. Yedid

    Robert A. Yedid

    Director

    July 2, 2024

     

     
    Get the next $VXRT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VXRT

    DatePrice TargetRatingAnalyst
    8/15/2024$4.00Outperform
    Oppenheimer
    12/29/2021$13.00 → $12.00Buy
    Jefferies
    11/2/2021$15.00Overweight
    Cantor Fitzgerald
    6/30/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/29/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $VXRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

    Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastfed infants and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population SOUTH SAN FRANCISCO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the publication in npj Vaccines of data from a double-blind, placebo-control

    1/15/26 8:00:00 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

    SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart or "the Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will participate in the Global BioInnovation Forum, a virtual gathering of senior leaders building and scaling next-generation life science and health innovation companies. Presentation Details: Speakers: Steven Lo, Chief Executive Officer, Sean Tucker, Ph.D., Founder and Chief Scientific Officer, and James F. Cummings, M.D., Chief Medical OfficerDate: Tuesday, January 13, 2026Time: 11:30am PT, 2:30pm ETRegistration and Web

    1/8/26 4:01:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

    Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline data expected in late 2026; Topline data from 400-person sentinel cohort anticipated in the first quarter of 2026 Reported additional supportive data from Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, demonstrating potential for improved protection against infection; Company continues to explore partnership opportunities Cash, cash equivalents and investments of $

    11/13/25 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Watson W. Mark bought $8,185 worth of shares (20,000 units at $0.41), increasing direct ownership by 19% to 124,125 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    12/5/25 5:46:47 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Heron Elaine J bought $15,921 worth of shares (40,000 units at $0.40), increasing direct ownership by 71% to 96,566 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    11/21/25 1:21:51 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Finney Kevin bought $61,934 worth of shares (166,668 units at $0.37), increasing direct ownership by 437% to 204,771 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    8/19/25 4:06:58 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Cummings James F. covered exercise/tax liability with 7,965 shares, decreasing direct ownership by 1% to 737,792 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    2/5/26 6:54:11 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, General Counsel Berg Edward B covered exercise/tax liability with 9,265 shares, decreasing direct ownership by 1% to 684,858 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    2/5/26 6:53:44 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, Chief Scientific Officer Tucker Sean covered exercise/tax liability with 9,265 shares, decreasing direct ownership by 1% to 731,225 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    2/5/26 6:53:18 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    SEC Filings

    View All

    Vaxart Inc filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Vaxart, Inc. (0000072444) (Filer)

    12/29/25 8:00:35 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Vaxart Inc

    10-Q - Vaxart, Inc. (0000072444) (Filer)

    11/13/25 4:16:20 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vaxart, Inc. (0000072444) (Filer)

    11/13/25 4:11:25 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Vaxart with a new price target

    Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00

    8/15/24 7:45:56 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on Vaxart with a new price target

    Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously

    12/29/21 7:23:57 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Vaxart with a new price target

    Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00

    11/2/21 7:42:45 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Leadership Updates

    Live Leadership Updates

    View All

    Concerned Vaxart Stockholders Respond to Inadequate Governance Announcements

    Believe Elevating W. Mark Watson – who Received only 56% of Votes Cast at Last Annual Meeting – to Lead Independent Director Fails to Deliver Real Reform Reiterate Intent to Vote Against Reverse Stock Split at September 19th Special Meeting ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD and David Whitney (collectively, the "Concerned Vaxart Stockholders"), who collectively beneficially own more than 2.6 million shares of Vaxart, Inc. (OTC:VXRT) ("Vaxart" or the "Company"), today issued a statement in response to the Company's app

    9/18/25 9:00:00 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Appoints W. Mark Watson as Lead Independent Director

    In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board's interests with stockholders Vaxart encourages all stockholders of record on July 29, 2025, who have not yet voted FOR the reverse stock split, to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced today that W. Mark Watson has been appointed Lead Independent Director. Mr. Watson is a Certified Public Accountant with over 50 years of experien

    9/17/25 4:05:01 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science and Technology Committee after a distinguished tenure of service. His retirement will be effective September 30, 2025. "It has been a profound privilege to serve as Vaxart's Chairman and be a part of this incredible Company's journey for so many years," said Mr. Finney. "I am immensely proud of what w

    9/2/25 4:30:52 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VXRT
    Financials

    Live finance-specific insights

    View All

    Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

    Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline data expected in late 2026; Topline data from 400-person sentinel cohort anticipated in the first quarter of 2026 Reported additional supportive data from Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, demonstrating potential for improved protection against infection; Company continues to explore partnership opportunities Cash, cash equivalents and investments of $

    11/13/25 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart to Host Upcoming Conference Calls

    Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart") today announced it will host two upcoming webcast conference calls. Third Quarter 2025 Financial ResultsVaxart will provide a business update and report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The third quarter financial results conference call can be a

    11/7/25 8:00:00 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

    HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 millionBoard of Directors authorizes new $100 million share repurchase program Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunitiesConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vacc

    11/5/25 4:01:00 PM ET
    $DVAX
    $VXRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $VXRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vaxart Inc (Amendment)

    SC 13G/A - Vaxart, Inc. (0000072444) (Subject)

    2/13/24 5:16:04 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Vaxart Inc

    SC 13G - Vaxart, Inc. (0000072444) (Subject)

    1/19/24 4:30:58 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Vaxart Inc

    SC 13G - Vaxart, Inc. (0000072444) (Subject)

    2/9/23 11:35:17 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care